Share

June 2019; 9 (3) ReviewOpen Access

Primary headache disorders

Five new things

Peter J. Goadsby
First published May 17, 2019, DOI: https://doi.org/10.1212/CPJ.0000000000000654
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
5993

Share

Article Information

vol. 9 no. 3 233-240
DOI: 
https://doi.org/10.1212/CPJ.0000000000000654
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received January 3, 2019
  • Accepted April 17, 2019
  • First Published May 17, 2019.

Article Versions

Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Disclosures

    1. Peter J. Goadsby
  1. Peter J. Goadsby
    2. Scientific Advisory Boards:

    1. I have consulted for the following commercial entities Alder Bio Allergan Amgen Autonomic Technologies Inc Dr Reddy's Laboratories Eli-Lilly Electrocore LLC eNeura Inc Novartis Scion Teva Pharmaceuticals Trigemina

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Up-to-Date Massachusetts Medical Society

    Patents:

    1. NONE

    Publishing Royalties:

    1. Lance JW, Goadsby PJ. Mechanism and Management of Headache. (7th ed.) New York: Elsevier, 2005

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Amgen, Eli-Lilly

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Trigemina, Inc, stock options

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. MedicoLegal work

  1. NIHR-Wellcome Trust King's Clinical Research Facility and SLaM Biomedical Research Centre, King's College London, UK; and Department of Neurology, University of California, San Francisco.
  1. Correspondence
    Dr. Goadsby peter.goadsby{at}kcl.ac.uk
View Full Text

Article usage

Article usage: May 2019 to April 2023

AbstractFullPdfSource
May 20192800160Highwire
Jun 20194331634673Highwire
Jul 20192931947596Highwire
Aug 201946971601Highwire
Sep 201922473151Highwire
Oct 201943708156Highwire
Nov 201914463143Highwire
Dec 20191426488Highwire
Jan 202018299114Highwire
Feb 20201227293Highwire
Mar 2020825060Highwire
Apr 202010377133Highwire
May 20206502116Highwire
Jun 2020436353Highwire
Jul 20201239182Highwire
Aug 202019390115Highwire
Sep 20201639092Highwire
Oct 20201338182Highwire
Nov 202010406103Highwire
Dec 20203245980Highwire
Jan 20211423660Highwire
Feb 20211024085Highwire
Mar 20212626565Highwire
Apr 20211723872Highwire
May 20212321659Highwire
Jun 20211120658Highwire
Jul 20211621678Highwire
Aug 20211324273Highwire
Sep 20211923265Highwire
Oct 2021918872Highwire
Nov 2021178953Highwire
Dec 2021167634Highwire
Jan 20222211642Highwire
Feb 20221810457Highwire
Mar 20222014085Highwire
Apr 202221153124Highwire
May 202223125106Highwire
Jun 2022325123110Highwire
Jul 20223517988Highwire
Aug 202246344118Highwire
Sep 20222725689Highwire
Oct 20221923589Highwire
Nov 20221521499Highwire
Dec 20221416976Highwire
Jan 20232921495Highwire
Feb 20232219493Highwire
Mar 202316224131Highwire
Apr 202314194126Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles